SuperworthAcrivon Therapeutics shares outstanding ACRV
Diluted shares outstanding, averaged over each quarter, from 2021.
- Latest quarter, to Jun 30, 2026
- 41.8M
- On a year earlier
- +8.8%
- more shares
Acrivon Therapeutics had 41.8M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 8.8% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 38.7M | +1% |
| FY2024 | 38.2M | +71% |
| FY2023 | 22.3M | +101% |
| FY2022 | 11.1M | +527% |
| FY2021 | 1.8M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 41.8M | +9% | |
| Q1 FY26 | 38.7M | +1% | |
| Q4 FY25 | 38.7M | +1% | |
| Q3 FY25 | 38.6M | +1% | |
| Q2 FY25 | 38.5M | +6% | |
| Q1 FY25 | 38.4M | +70% | |
| Q4 FY24 | 38.2M | +71% | |
| Q3 FY24 | 38.1M | +73% | |
| Q2 FY24 | 36.1M | +64% | |
| Q1 FY24 | 22.6M | +3% | |
| Q4 FY23 | 22.3M | +101% | |
| Q3 FY23 | 22.1M | +1142% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Acrivon Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.